Key Takeaways

• Ag biotech firms are turning to contract development and manufacturing organizations (CDMOs) to enhance R&D speed and reduce costs.
• Localized knowledge and field testing are essential for the success of crop protection products across different biogeographical regions.
• IdeeLab aims to develop next-generation biological products and expand its market presence in Latin America and beyond.

Innovative Solutions for Ag Biotech

The ag biotech sector is under pressure to accelerate research and development (R&D) while cutting costs. A promising solution is the implementation of contract development and manufacturing organizations (CDMOs), a strategy already recognized in the pharmaceutical industry and now gaining traction in agricultural biotechnology.

According to Gilson Manfio, PhD, head of R&D and innovation at IdeeLab, when developing new crop protection products, it is vital to consider not just R&D speed but also the “biogeographical context.” Manfio explains that while many technologies may perform well in their country of origin, they often fail to deliver similar results when deployed in different climates.

IdéeLab focuses on providing not just the necessary infrastructure and regulatory expertise but also local partnerships and regional insights crucial for product success. Currently, the organization assists companies in launching products tailored for the Latin American market, with potential for a globally replicable model.

IdeeLab strives to create sustainable biological technologies for the agricultural input market, emphasizing metabolite-based and protein-peptide-based biologicals. These innovations promise a range of advantages over traditional live cell-based products, including improved tank mix compatibility, extended shelf life, and versatility in formulations. This allows for the creation of hybrid products that combine immediate effects with longer-lasting benefits.

The role of CDMOs is particularly significant in enhancing R&D efficiency in Brazil, where the unique tropical agricultural conditions require different approaches than those found in temperate regions like Europe and the U.S. CDMOs work closely with client R&D teams, enabling timely testing of specific pests and diseases that may not be feasible in a client’s laboratory located in colder regions.

When it comes to product development specifics, the initial stages for biopesticides and bioinsecticides may share common methodologies, focusing on the isolation and screening of beneficial microorganisms and metabolites. However, as projects evolve, more complex validations using model plant species and actual crops are conducted to evaluate growth promotion and pest resistance.

Regulatory considerations also impact product development, particularly in Brazil. New crop protection technologies require a testing license from the Brazilian regulatory agency (MAPA), while biological physiologies may not. Validation for diverse climatic conditions typically requires collaboration with third-party service providers, which complicates factory setups, often necessitating separate production lines for different product categories.

Looking ahead, IdeeLab is well-positioned as a key partner for numerous ag input companies aiming to enter the biological agricultural market in Brazil and Latin America. The firm offers comprehensive solutions, from live cell products to advanced microbial metabolites and proteins that can trigger physiological responses in plants.

By second half of 2025, IdeeLab plans to inaugurate a new biofactory, significantly expanding its manufacturing capabilities for both cell-based and protein/peptide technologies. Future growth will focus on manufacturing expansion, attracting clients for advanced technology products, and broadening R&D to encompass areas such as bioinsecticides and bioherbicides. International expansion is also part of the strategic vision, reinforcing the company’s commitment to a globally integrated approach in the ag biotech sector.

The content above is a summary. For more details, see the source article.